Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100026/S100

NeuroPace RNS System

NeuroPace, Inc. · Decision date Jun 17, 2026

FDA DECISIONP100026/S100

What did the FDA approve?

FDA records P100026/S100 as a supplement to PMA P100026, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jun 17, 2026.

FDA approval order statement

approval for migration of the Patient Data Management System from on-site server to cloud service
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Jun 17, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P100026/S100
Regulatory pathway
PMA supplement
Product code
PFN
Decision code
APPR
Decision date
Jun 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implanted brain stimulator for epilepsy.

Product code
PFN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P100026/S100 received

    Application receipt date recorded by FDA.

  2. P100026/S100 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P100026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100026

Product / regulatory recordCompanyPathwayDecision dateSource
NeuroPace, Inc.PMA supplementAug 18, 2025FDA
NeuroPace, Inc.PMA supplementFeb 20, 2026FDA
NeuroPace, Inc.PMA supplementMay 28, 2026FDA
NeuroPace, Inc.PMA supplementAug 19, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

NeuroPace, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
455 N Bernardo Ave., Mountain View, CA, 94043

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records